Versanis, With $70m Series A, To Advance Abandoned Novartis Drug In Obesity

 
• By Joseph Haas

The failed muscle-adding antibody could offer a superior profile in obesity by reducing body fat composition while increasing lean mass, the firm believes.

Hand holds the magnifying glass in front of an open notebook. Among the many icons, attention is focused on the money icon. Financial operations, banking, lending, etc.
With $70m in series A cash, Versanis hopes to develop obesity drug to take on semaglutide

More from Strategy

More from Business